GALT Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 50.10%

Insider Buying (Last 12 Months): $48,945.70

Insider Selling (Last 12 Months): $162,703.90

Galectin Therapeutics Insider Trading History Chart

Galectin Therapeutics Share Price & Price History

^$1.38

▲ +0.01 (0.73%)

As of 04/17/2025 05:00 PM ET

Days: 30 | 90 | 365

Galectin Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/30/2024	Harold H Shlevin	Director	Buy	6,500	$1.16	$7,540.00	15,206
12/24/2024	Richard A. Zordani, Jr.	Director	Buy	10,000	$0.82	$8,200.00	42,083
12/23/2024	Jack W Callicutt	CFO	Sell	40,000	$0.89	$35,600.00	7,614
12/23/2024	Joel Lewis	CEO	Sell	56,000	$0.89	$49,840.00	897,012
12/23/2024	Khurram Jamil	Insider	Sell	13,654	$0.88	$12,015.52	26,346
10/23/2024	Kary Eldred	Director	Buy	500	$2.60	$1,300.00	50,213
10/16/2024	Kevin D. Freeman	Director	Buy	5,000	$2.70	$13,500.00	33,469
8/23/2024	Richard A. Zordani, Jr.	Director	Buy	1,759	$2.30	$4,045.70	32,083
4/30/2024	Richard A. Zordani, Jr.	Director	Buy	1,000	$3.52	$3,520.00	1,000
4/24/2024	Joel Lewis	CEO	Buy	1,000	$3.39	$3,390.00	2,000
4/22/2024	James C Czirr	Major Shareholder	Sell	21,323	$3.06	$65,248.38	5,925,884
4/22/2024	Kevin D. Freeman	Director	Buy	2,500	$2.98	$7,450.00	25,969
1/16/2024	Kary Eldred	Director	Buy	500	$1.79	$895.00	49,313
7/19/2023	Kary Eldred	Director	Buy	1,598	$1.79	$2,860.42	48,813
2/21/2023	Kary Eldred	Director	Buy	1,000	$1.59	$1,590.00	47,215
2/16/2023	Joel Lewis	CEO	Buy	1,000	$1.52	$1,520.00	1,000
1/25/2023	Kary Eldred	Director	Buy	1,300	$1.11	$1,443.00	46,215
11/17/2022	Jack W Callicutt	CFO	Buy	4,000	$1.32	$5,280.00	7,614
10/28/2022	Kevin D. Freeman	Director	Buy	10,000	$1.41	$14,100.00	75,000
7/28/2022	Richard A. Zordani, Jr.	Director	Buy	5,000	$2.50	$12,500.00	29,583
5/19/2022	Kevin D. Freeman	Director	Buy	5,000	$1.33	$6,650.00	65,000

See Full Table

SEC Filings (Institutional Ownership Changes) for Galectin Therapeutics (NASDAQ:GALT)

11.68% of Galectin Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Galectin Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/16/2025	Wealth Enhancement Advisory Services LLC	36,141	$44K	0.0%	-29.8%	0.057%
3/17/2025	Wealth Enhancement Advisory Services LLC	51,510	$66K	0.0%	+46.8%	0.082%
2/17/2025	Vivaldi Capital Management LP	45,628	$56K	0.0%	+89.9%	0.073%
2/17/2025	Bank of America Corp DE	38,358	$49K	0.0%	+101.4%	0.061%
2/14/2025	Northern Trust Corp	244,274	$0.32M	0.0%	+4.3%	0.389%
2/14/2025	Two Sigma Securities LLC	28,571	$37K	0.0%	N/A	0.046%
2/13/2025	Barclays PLC	54,634	$71K	0.0%	+91.1%	0.087%
2/12/2025	Geode Capital Management LLC	870,589	$1.12M	0.0%	+0.9%	1.387%
2/12/2025	JPMorgan Chase & Co.	59,693	$77K	0.0%	+94.9%	0.095%
2/11/2025	LPL Financial LLC	138,928	$0.18M	0.0%	+69.6%	0.221%
2/10/2025	Commonwealth Equity Services LLC	134,518	$0.17M	0.0%	-72.2%	0.214%
2/7/2025	HighTower Advisors LLC	22,486	$29K	0.0%	N/A	0.036%
2/7/2025	Inspire Advisors LLC	21,095	$27K	0.0%	+86.3%	0.034%
2/7/2025	PNC Financial Services Group Inc.	20,000	$26K	0.0%	N/A	0.032%
2/4/2025	Bank of New York Mellon Corp	50,826	$66K	0.0%	+19.0%	0.081%
1/31/2025	D.A. Davidson & CO.	19,000	$25K	0.0%	-38.3%	0.030%
1/31/2025	Sanctuary Advisors LLC	58,413	$73K	0.0%	-26.2%	0.093%
1/29/2025	Retirement Guys Formula LLC	155,343	$0.20M	0.1%	+143.4%	0.248%
1/29/2025	Sovran Advisors LLC	186,014	$0.24M	0.0%	N/A	0.296%
1/27/2025	Stratos Wealth Partners LTD.	51,550	$66K	0.0%	+27.4%	0.082%
1/21/2025	Geneos Wealth Management Inc.	388,935	$0.50M	0.0%	+10.2%	0.620%
1/17/2025	Traynor Capital Management Inc.	55,670	$72K	0.0%	+29.9%	0.089%
1/10/2025	Wealth Enhancement Advisory Services LLC	51,369	$66K	0.0%	+46.4%	0.082%
12/26/2024	JPMorgan Chase & Co.	30,628	$84K	0.0%	+161.3%	0.049%
11/25/2024	Sanctuary Advisors LLC	79,113	$0.22M	0.0%	-21.4%	0.126%
11/19/2024	Barclays PLC	28,587	$79K	0.0%	+309.0%	0.046%
11/18/2024	Soltis Investment Advisors LLC	140,750	$0.39M	0.0%	N/A	0.226%
11/16/2024	Geode Capital Management LLC	862,542	$2.37M	0.0%	+2.5%	1.385%
11/15/2024	Barclays PLC	28,587	$79K	0.0%	+309.0%	0.046%
11/15/2024	Kovitz Investment Group Partners LLC	42,540	$0.12M	0.0%	N/A	0.068%
11/15/2024	State Street Corp	251,014	$0.69M	0.0%	+9.3%	0.403%
11/13/2024	D.A. Davidson & CO.	30,771	$85K	0.0%	-36.9%	0.049%
10/28/2024	Gladstone Institutional Advisory LLC	21,750	$60K	0.0%	N/A	0.035%
10/21/2024	Retirement Guys Formula LLC	63,817	$0.18M	0.1%	+55.1%	0.103%
9/5/2024	Sanctuary Advisors LLC	100,658	$0.23M	0.0%	N/A	0.162%
8/14/2024	Squarepoint Ops LLC	84,074	$0.19M	0.0%	+75.4%	0.135%
8/14/2024	Marshall Wace LLP	18,825	$43K	0.0%	N/A	0.030%
8/1/2024	Rhumbline Advisers	19,275	$44K	0.0%	N/A	0.031%
7/31/2024	Commonwealth Equity Services LLC	483,351	$1.09M	0.0%	+317.6%	0.778%
7/26/2024	Bank of New York Mellon Corp	64,423	$0.15M	0.0%	N/A	0.104%
7/24/2024	Traynor Capital Management Inc.	42,871	$97K	0.0%	+23.5%	0.069%
5/10/2024	Vanguard Group Inc.	1,979,891	$4.73M	0.0%	+2.0%	3.198%
5/7/2024	Wealthspire Advisors LLC	398,374	$0.95M	0.0%	+116.7%	0.644%
5/4/2024	Geneos Wealth Management Inc.	408,850	$0.98M	0.0%	-0.9%	0.660%
4/19/2024	Retirement Guys Formula LLC	33,732	$81K	0.0%	+56.9%	0.054%
2/6/2024	Solutions 4 Wealth Ltd	36,085	$60K	0.2%	N/A	0.058%
2/2/2024	Atria Wealth Solutions Inc.	249,800	$0.42M	0.0%	-3.8%	0.404%
2/1/2024	Cutter & CO Brokerage Inc.	117,488	$0.20M	0.1%	-9.3%	0.190%
1/22/2024	Retirement Guys Formula LLC	21,500	$36K	0.0%	+87.0%	0.035%
1/9/2024	Beacon Capital Management LLC	23,905	$40K	0.0%	+89.6%	0.039%
11/8/2023	D.A. Davidson & CO.	37,825	$73K	0.0%	+15.2%	0.061%
10/16/2023	Traynor Capital Management Inc.	34,707	$67K	0.0%	N/A	0.056%
10/11/2023	AE Wealth Management LLC	26,841	$52K	0.0%	+72.7%	0.043%
8/3/2023	Atria Wealth Solutions Inc.	260,800	$0.38M	0.0%	-3.7%	0.439%
7/25/2023	Summit Trail Advisors LLC	20,000	$29K	0.0%	N/A	0.034%
7/13/2023	Cambridge Investment Research Advisors Inc.	134,332	$0.19M	0.0%	-5.7%	0.226%
5/12/2023	Independent Advisor Alliance	36,100	$76K	0.0%	N/A	0.061%
5/9/2023	Wealthspire Advisors LLC	183,862	$0.39M	0.0%	N/A	0.309%
5/9/2023	Wedbush Securities Inc.	15,498	$33K	0.0%	-36.7%	0.026%
4/25/2023	Geneos Wealth Management Inc.	427,400	$0.90M	0.1%	-1.7%	0.719%
2/7/2023	Commonwealth Equity Services LLC	101,522	$0.11M	0.0%	+165.6%	0.170%
2/7/2023	Benjamin F. Edwards & Company Inc.	34,412	$39K	0.0%	+78.7%	0.058%
2/3/2023	Cutter & CO Brokerage Inc.	129,488	$0.15M	0.0%	-23.6%	0.217%
1/31/2023	Geneos Wealth Management Inc.	434,800	$0.49M	0.0%	-2.3%	0.729%
11/7/2022	D.A. Davidson & CO.	32,810	$53K	0.0%	-27.6%	0.055%
7/28/2022	D.A. Davidson & CO.	45,335	$59K	0.0%	-18.0%	0.076%
7/19/2022	Commonwealth Equity Services LLC	38,220	$50K	0.0%	+42.1%	0.064%
5/4/2022	Advisor Group Holdings Inc.	1,265,820	$2.04M	0.0%	+1.5%	2.133%
5/4/2022	Commonwealth Equity Services LLC	26,902	$43K	0.0%	+59.2%	0.045%
5/3/2022	Cutter & CO Brokerage Inc.	169,578	$0.27M	0.1%	-7.6%	0.286%
2/9/2022	Geneos Wealth Management Inc.	480,767	$1M	0.0%	-2.2%	0.810%
2/7/2022	Benjamin F. Edwards & Company Inc.	29,615	$61K	0.0%	+25.5%	0.050%
2/7/2022	Ameritas Advisory Services LLC	44,232	$92K	0.0%	N/A	0.075%
2/3/2022	Cambridge Investment Research Advisors Inc.	153,027	$0.32M	0.0%	-7.0%	0.258%
2/3/2022	Advisor Group Holdings Inc.	1,247,401	$2.58M	0.0%	-2.1%	2.102%
11/16/2021	Squarepoint Ops LLC	39,191	$0.15M	0.0%	-30.2%	0.066%
11/15/2021	Capstone Investment Advisors LLC	42,260	$0.16M	0.0%	N/A	0.071%
11/12/2021	Ameritas Investment Company LLC	44,232	$0.17M	0.0%	+12.7%	0.075%
11/12/2021	Centaurus Financial Inc.	22,614	$88K	0.0%	+44.8%	0.038%
11/12/2021	Geode Capital Management LLC	540,866	$2.10M	0.0%	+32.2%	0.912%
11/10/2021	Buckingham Strategic Wealth LLC	10,734	$42K	0.0%	N/A	0.018%
11/9/2021	BlackRock Inc.	787,582	$3.06M	0.0%	-0.8%	1.328%
11/8/2021	Keybank National Association OH	100,000	$0.39M	0.0%	N/A	0.169%
11/4/2021	QCI Asset Management Inc. NY	55,000	$0.21M	0.0%	+120.0%	0.093%
11/2/2021	Raymond James & Associates	13,096	$51K	0.0%	N/A	0.022%
11/2/2021	Benjamin F. Edwards & Company Inc.	23,600	$92K	0.0%	-32.0%	0.040%
11/2/2021	Cambridge Investment Research Advisors Inc.	164,498	$0.64M	0.0%	-2.3%	0.277%
10/29/2021	Commonwealth Equity Services LLC	11,902	$46K	0.0%	N/A	0.020%
10/8/2021	Wedbush Securities Inc.	30,998	$0.12M	0.0%	+72.2%	0.052%
9/3/2021	Parametric Portfolio Associates LLC	56,047	$0.18M	0.0%	+62.9%	0.096%
8/25/2021	Marshall Wace LLP	47,509	$0.15M	0.0%	N/A	0.082%
8/17/2021	Millennium Management LLC	568,690	$1.82M	0.0%	N/A	0.979%
8/17/2021	Boothbay Fund Management LLC	10,965	$35K	0.0%	N/A	0.019%
8/16/2021	Squarepoint Ops LLC	56,128	$0.18M	0.0%	N/A	0.097%
8/16/2021	Ameritas Investment Company LLC	39,232	$0.13M	0.0%	N/A	0.068%
8/16/2021	LMR Partners LLP	19,285	$62K	0.0%	N/A	0.033%
8/16/2021	Charles Schwab Investment Management Inc.	17,413	$56K	0.0%	-77.5%	0.030%
8/16/2021	State Street Corp	158,759	$0.51M	0.0%	-74.2%	0.273%
8/16/2021	Tibra Equities Europe Ltd	98,700	$0.32M	0.1%	N/A	0.170%
8/16/2021	Marshall Wace LLP	47,509	$0.15M	0.0%	N/A	0.082%

Data available starting January 2016

See Full Table

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Today's Range

Now: $1.38

$1.33

$1.45

50 Day Range

MA: $1.47

$1.22

$1.77

52 Week Range

Now: $1.38

$0.73

$3.78

Volume

180,968 shs

Average Volume

318,835 shs

Market Capitalization

$87.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79

Who are the company insiders with the largest holdings of Galectin Therapeutics?: Galectin Therapeutics' top insider investors include:
James C Czirr (Major Shareholder)
Joel Lewis (CEO)
Kary Eldred (Director)
Richard A Jr Zordani (Director)
Kevin D Freeman (Director)
Khurram Jamil (Insider)
Harold H Shlevin (Director)
Jack W Callicutt (CFO)
Learn More about top insider investors at Galectin Therapeutics.
Who are the major institutional investors of Galectin Therapeutics?: Galectin Therapeutics' top institutional shareholders include:
Wealth Enhancement Advisory Services LLC — 0.06%
FNY Investment Advisers LLC — 0.00%
Learn More about top institutional investors of Galectin Therapeutics stock.
Which major investors are selling Galectin Therapeutics stock?: In the last quarter, GALT stock was sold by these institutional investors:
Wealth Enhancement Advisory Services LLC
Within the last year, company insiders that have sold Galectin Therapeutics company stock include:
James C Czirr (Major Shareholder)
Joel Lewis (CEO)
Kary Eldred (Director)
Richard A Jr Zordani (Director)
Learn More investors selling Galectin Therapeutics stock.